Ernexa Therapeutics Inc. - Common Stock (ERNA)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 27, 2026Investment Snapshot
- P/B of 2.53 — trading above book value
- Piotroski F-Score 6/9 — moderate financial health
- Loss-making — negative ROE of -1,632.0%
- Revenue growing at 756% annually
Ernexa Therapeutics Inc. - Common Stock (ERNA) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $6 million . Key value metrics: P/B ratio 2.53, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Ernexa Therapeutics Inc. - Common Stock — Fundamental Analysis Summary
On financial health, ERNA shows a moderate Piotroski F-Score of 6/9, and negative return on equity of -1,632.0% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.63.
StockPik's composite Value Score for ERNA is 49/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ERNA reports a high gross margin of 83.5% (sector average: 33.5%) and a negative operating margin of -1,629.4%.
ERNA shows revenue growing at 756% year-over-year, with earnings growing at 68%.